← Eichor
Study identifier: NCT06650995 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure

Condition: HFpEF - Heart Failure With Preserved Ejection Fraction · Atrial Fibrillation  ·  Sponsor: Technical University of Munich

PhaseNA
Planned participants40
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

The investigators analyze the impact of exercise and ablation in patients with symptomatic short-persistent atrial fibrillation (Afib) and heart failure with preserved ejection fraction (HFpEF). It is hypothesized that the combination of ablation and exercise better improves peak oxygen consumption (VO2peak) through improvement of peripheral (exercise training) and central (ablation) adaptations. Exercise intervention will contain a 12-week combined, video-based, supervised, endurance, resistance and respiratory training.

This description comes directly from the study's public registry record.

Talk to the study team

Martin Halle, Professor  ·  +49 8928924441  ·  martin.halle@mri.tum.de

Manuel Rattka, MD  ·  +49 8928924441  ·  manuel.rattka@mri.tum.de

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Medicine, Division of Prevention and Sports Medicine TU MunichMunich, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06650995